Trial Profile
The study evaluating HSP27 expression within a breast cancer cohort and its implications in cellular responsiveness to cMET inhibition and neratinib.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Jan 2018
Price :
$35
*
At a glance
- Drugs Neratinib (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 12 Jan 2018 New trial record
- 09 Dec 2017 Results presented at the 40th Annual San Antonio Breast Cancer Symposium